Raily Aesthetic Medicine International Holdings Limited projects a loss of approximately RMB2.00 million for the year ended December 31, 2025, notably lower than the RMB63.00 million loss recorded for 2024. The Group also anticipates a profit attributable to the owners of the parent of approximately RMB2.00 million for 2025, compared with a loss of about RMB59.00 million for the prior year.

The announcement attributes the improved performance mainly to the absence of the one-off impairment loss recognized in 2024 and an overall improvement in profit margins. The Group’s final consolidated annual results for 2025, expected by the end of March 2026, may be subject to amendments upon completion of the audit review.

Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.